Boston Scientific Remains Flat After Meeting Earnings

By Chris Lange Updated Jan 13, 1:54AM EST · Published Oct 26, 10:45AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Boston Scientific Remains Flat After Meeting Earnings — © Thinkstock

When Boston Scientific Corp. (NYSE: BSX) reported its third-quarter earnings results before the markets opened on Wednesday, it said that it had $0.27 in earnings per share (EPS) and $2.11 billion in revenue. The consensus estimates from Thomson Reuters had called for $0.27 in EPS and revenue of $2.07 billion. The same period of last year reportedly had EPS of $0.24 and $1.89 billion in revenue.

During this quarter, Boston Scientific entered into a definitive agreement and commenced a cash tender offer to acquire EndoChoice Holdings, which offers physicians a broad portfolio of products to treat gastrointestinal conditions, for roughly $210 million.

Also in the quarter, the company received U.S. Food and Drug Administration (FDA) approval for the Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance conditional labeling for all previously implanted Emblem S-ICD Systems.

[nativounit]

In terms of its segment revenues, Boston Scientific reported:

MedSurg revenues grew 15% (14% operational and 10% organic).
Cardiovascular revenues increased 13% (12% operational and organic).
Rhythm Management revenues increased 4% (3% operational and organic).

As for fourth-quarter guidance, the company expects to see EPS in the range of $0.27 to $0.29 and revenues between $2.14 billion and $2.19 billion. The consensus estimates call for $0.29 in EPS and $2.15 billion in revenue.

Mike Mahoney, board chair and chief executive of Boston Scientific, commented:

Our differentiated products and services continue to make a meaningful impact for our customers and the patients they treat, as shown by very strong revenue growth in the third quarter and year to date. Our global team is delivering excellent performance across our various business units and geographies.

On the books, Boston Scientific cash and cash equivalents totaled $237 million at the end of the quarter, down from $319 million at the end of 2015.

Shares of Boston Scientific were trading at $22.44 on Wednesday, with a consensus analyst price target of $27.55 and a 52-week trading range of $15.67 to $24.79.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.